{
    "nctId": "NCT02078752",
    "briefTitle": "A Study Of PF-06647263 In Patients With Advanced Solid Tumors",
    "officialTitle": "A FIRST-IN-HUMAN PHASE 1, DOSE ESCALATION, SAFETY AND PHARMACOKINETIC STUDY OF PF-06647263 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS",
    "overallStatus": "TERMINATED",
    "conditions": "Neoplasms, Triple-Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Number of Participants With Dose Limiting Toxicities (DLTs) (Part 1)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for whom no standard therapy is available\n* Performance Status of 0 or 1\n* Adequate bone marrow, kidney, and liver function\n* Part 2 includes advanced triple negative breast cancer patients.\n\nExclusion Criteria:\n\n* Brain metastases requiring steroids\n* Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start\n* Active and clinically significant bacterial, fungal or viral infection",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}